BioCentury's websites will be down for upgrades starting at 9 p.m. PDT on Monday, August 26. We expect the downtime to last no more than 6 hours, and we apologize for any inconvenience.

6:15 PM
 | 
Aug 17, 2009
 |  BC Extra  |  Company News

NICE recommends ustekinumab

The U.K.'s NICE issued a final appraisal determination recommending use of Stelara ustekinumab from Johnson & Johnson (NYSE:JNJ) to treat plaque psoriasis in adults where the disease is severe as defined by a total PASI of 10 or more and a...

Read the full 194 word article

User Sign in

Trial Subscription

Get a 4-week free trial subscription to BioCentury Extra

Article Purchase

$50 USD
More Info >